Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.62 |
| ▸ | JAK1 | P23458 | 3/20 | 0.62 |
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074856 | 0.92 | JAK3 (0.65) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913304 | 0.91 | JAK3 (0.64) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL912989 | 0.90 | JAK3 (0.78) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL914769 | 0.89 | JAK3 (0.65) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL13074514 | 0.87 | JAK3 (0.66) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913068 | 0.86 | JAK3 (0.62) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913975 | 0.86 | JAK3 (0.56) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL17021397 | 0.85 | BRAF (0.51) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL913838 | 0.85 | JAK3 (0.57) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL914456 | 0.84 | JAK3 (0.54) | JAK3IRAK4JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885IRAK4 48/4885JAK2 2/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885IRAK4 48/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.